Rebekah Tucker
Family · Tifton, GANPI 1265196869
Payments from drug & device makers
Across 214 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$631
- AstraZeneca$562
- Novo Nordisk$415
- Lilly USA, LLC$351
- Dexcom, Inc.$274
- Pfizer$242
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,619100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 45 | $631 |
| AstraZeneca | 31 | $562 |
| Novo Nordisk | 24 | $415 |
| Lilly USA, LLC | 24 | $351 |
| Dexcom, Inc. | 16 | $274 |
| Pfizer | 12 | $242 |
| Amgen | 14 | $241 |
| GSK | 11 | $179 |
| Exact Sciences | 5 | $93 |
| Bayer | 4 | $93 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $62 |
| Shield Therapeutics Inc | 3 | $61 |
| Boehringer Ingelheim | 3 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $50 |
| Idorsia Pharmaceuticals US Inc | 3 | $49 |
| Amarin Pharma, Inc. | 2 | $35 |
| Medtronic | 1 | $25 |
| Astellas Pharma US Inc | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Novartis | 1 | $24 |
| Insulet Corporation | 1 | $22 |
| Eisai Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $10 |
How this compares
$3,619 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 89 | $127,763 |
| TrulicityDulaglutide | 95 | $117,530 |
| JardianceEmpagliflozin | 67 | $83,744 |
| EliquisApixaban | 78 | $81,922 |
| OzempicSemaglutide | 60 | $69,818 |
| FarxigaDapagliflozin Propanediol | 51 | $66,746 |
| RybelsusSemaglutide | 24 | $40,240 |
| VraylarCariprazine Hcl | 20 | $39,563 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $33,638 |
| XareltoRivaroxaban | 30 | $25,428 |
| JanuviaSitagliptin Phosphate | 18 | $23,305 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 28 | $22,514 |
| LinzessLinaclotide | 15 | $16,085 |
| MyrbetriqMirabegron | 13 | $16,058 |
| BrilintaTicagrelor | 19 | $15,289 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $351 | $245,293184 claims |
| Novo NordiskOzempic, Rybelsus | $415 | $110,05884 claims |
| Boehringer IngelheimJardiance | $59 | $83,74467 claims |
| AstraZenecaFarxiga, Brilinta | $562 | $82,03570 claims |
| PfizerEliquis | $242 | $81,92278 claims |
| AbbVieVraylar, Linzess, Synthroid | $631 | $59,35280 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $179 | $39,76145 claims |
| Johnson & JohnsonXarelto | $16 | $25,42830 claims |
| Astellas Pharma US IncMyrbetriq | $25 | $16,05813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.
Other family in Tifton
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.